A Phase 2 interventional study of LY3454738 in Atopic Dermatitis, sponsored by Eli Lilly and Company. Terminated at 66 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Screening
This platform trial is designed to enable the investigation of many interventions for AD by means of the introduction of new interventional specific addenda (ISAs) over time. At the inception of this platform trial, at least 1 ISA will be available. Additional ISAs will be added to the platform trial over time.
1,419 studies on the registry are indexed under Dermatitis, Atopic; 258 are open to participants now.
This study's enrollment of 317 is above the median of 83 across 1,125 interventional studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Eli Lilly and Company is the lead sponsor of 2,048 studies on the registry; 140 are open to participants now.
Of its 521 completed or terminated interventional studies of FDA-regulated products, 341 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Present with a diagnosis of atopic dermatitis (AD) at least 12 months prior to screening
Exclusion Criteria:
Have a history of eczema herpeticum:
Note: Participants who fail screening due to this criterion should not be rescreened until at least 4 weeks after screen failure and at least 2 weeks after resolution of the infection.
Participants are assigned to the LY3454738 ISA.
Drug: LY3454738
Administered subcutaneously (SC)
Number of Participants Allocated to FR01 ISA
Time frame: Screening to Randomization (Up to 90 Days)
This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Eli Lilly and Company